{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:54:31Z","timestamp":1790805271000,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Traditional methods employed to discover new antibiotics are both a time-consuming and financially-taxing venture. This has led researchers to mine existing libraries of clinical molecules in order to repurpose old drugs for new applications (as antimicrobials). Such an effort led to the discovery of auranofin, a drug initially approved as an anti-rheumatic agent, which also possesses potent antibacterial activity in a clinically achievable range. The present study demonstrates auranofin\u2019s antibacterial activity is a complex process that involves inhibition of multiple biosynthetic pathways including cell wall, DNA, and bacterial protein synthesis. We also confirmed that the lack of activity of auranofin observed against Gram-negative bacteria is due to the permeability barrier conferred by the outer membrane. Auranofin\u2019s ability to suppress bacterial protein synthesis leads to significant reduction in the production of key methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (MRSA) toxins. Additionally, auranofin is capable of eradicating intracellular MRSA present inside infected macrophage cells. Furthermore, auranofin is efficacious in a mouse model of MRSA systemic infection and significantly reduces the bacterial load in murine organs including the spleen and liver. Collectively, this study provides valuable evidence that auranofin has significant promise to be repurposed as a novel antibacterial for treatment of invasive bacterial infections.\n                  <\/jats:p>","DOI":"10.1038\/srep22571","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T06:00:53Z","timestamp":1456984853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":205,"title":["Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens"],"prefix":"10.1038","volume":"6","author":[{"given":"Shankar","family":"Thangamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa F. N.","family":"Abushahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago J. P.","family":"Sobreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E.","family":"Hedrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lake N.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"key":"BFsrep22571_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ja.2014.142","volume":"68","author":"H Mohammad","year":"2015","unstructured":"Mohammad, H., Mayhoub, A. S., Cushman, M. & Seleem, M. N. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant Staphylococci. The Journal of antibiotics 68, 259\u2013266 (2015).","journal-title":"The Journal of antibiotics"},{"key":"BFsrep22571_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0140-6736(02)07877-7","volume":"359","author":"Y Gillet","year":"2002","unstructured":"Gillet, Y. et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359, 753\u2013759 (2002).","journal-title":"Lancet"},{"key":"BFsrep22571_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1128\/CMR.00081-09","volume":"23","author":"MZ David","year":"2010","unstructured":"David, M. Z. & Daum, R. S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23, 616\u2013687 (2010).","journal-title":"Clin Microbiol Rev"},{"key":"BFsrep22571_CR4","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.1086\/598189","volume":"48","author":"CK Naber","year":"2009","unstructured":"Naber, C. K. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 48 Suppl 4, S231\u2013237 (2009).","journal-title":"Clin Infect Dis"},{"key":"BFsrep22571_CR5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jpc.12750","volume":"51","author":"J Er","year":"2015","unstructured":"Er, J., Wallis, P., Maloney, S. & Norton, R. Paediatric bacteraemias in tropical Australia. Journal of paediatrics and child health 51, 437\u2013442 (2015).","journal-title":"Journal of paediatrics and child health"},{"key":"BFsrep22571_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","volume":"1","author":"K Hiramatsu","year":"2001","unstructured":"Hiramatsu, K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. The Lancet infectious diseases 1, 147\u2013155 (2001).","journal-title":"The Lancet infectious diseases"},{"key":"BFsrep22571_CR7","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1128\/AAC.00714-10","volume":"54","author":"JB Locke","year":"2010","unstructured":"Locke, J. B. et al. Elevated Linezolid Resistance in Clinical cfr-Positive Staphylococcus aureus Isolates Is Associated with Co-Occurring Mutations in Ribosomal Protein L3. Antimicrobial agents and chemotherapy 54, 5352\u20135355 (2010).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR8","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2174\/1381612821666150310104416","volume":"21","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Mohammad, H., Younis, W. & Seleem, M. N. Drug Repurposing for the Treatment of Staphylococcal Infections. Current pharmaceutical design 21, 2089\u20132100 (2015).","journal-title":"Current pharmaceutical design"},{"key":"BFsrep22571_CR9","doi-asserted-by":"publisher","first-page":"11596","DOI":"10.1038\/srep11596","volume":"5","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Younis, W. & Seleem, M. N. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections. Scientific reports 5, 11596 (2015).","journal-title":"Scientific reports"},{"key":"BFsrep22571_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/448645a","volume":"448","author":"CR Chong","year":"2007","unstructured":"Chong, C. R. & Sullivan, D. J. Jr. New uses for old drugs. Nature 448, 645\u2013646 (2007).","journal-title":"Nature"},{"key":"BFsrep22571_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/nm.2758","volume":"18","author":"A Debnath","year":"2012","unstructured":"Debnath, A. et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nature medicine 18, 956\u2013960 (2012).","journal-title":"Nature medicine"},{"key":"BFsrep22571_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10534-014-9743-6","volume":"27","author":"MI Cassetta","year":"2014","unstructured":"Cassetta, M. I., Marzo, T., Fallani, S., Novelli, A. & Messori, L. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 27, 787\u2013791 (2014).","journal-title":"Biometals"},{"key":"BFsrep22571_CR13","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1504022112","volume":"112","author":"MB Harbut","year":"2015","unstructured":"Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proceedings of the National Academy of Sciences of the United States of America 112, 4453\u20134458 (2015).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep22571_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jinorgbio.2014.05.008","volume":"138","author":"Y Hokai","year":"2014","unstructured":"Hokai, Y. et al. Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. J Inorg Biochem 138, 81\u201388 (2014).","journal-title":"J Inorg Biochem"},{"key":"BFsrep22571_CR15","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1093\/jac\/dkv163","volume":"70","author":"L Aguinagalde","year":"2015","unstructured":"Aguinagalde, L. et al. Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. The Journal of antimicrobial chemotherapy 70, 2608\u20132617 (2015).","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"BFsrep22571_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ja.2012.77","volume":"65","author":"NM Haste","year":"2012","unstructured":"Haste, N. M. et al. Activity of the thiopeptide antibiotic nosiheptide against contemporary strains of methicillin-resistant Staphylococcus aureus. J Antibiot 65, 593\u2013598 (2012).","journal-title":"J Antibiot"},{"key":"BFsrep22571_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1128\/AAC.02005-12","volume":"57","author":"CP Randall","year":"2013","unstructured":"Randall, C. P., Mariner, K. R., Chopra, I. & O\u2019Neill, A. J. The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens. Antimicrobial agents and chemotherapy 57, 637\u2013639 (2013).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1128\/AAC.25.6.701","volume":"25","author":"P Viljanen","year":"1984","unstructured":"Viljanen, P. & Vaara, M. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrobial agents and chemotherapy 25, 701\u2013705 (1984).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1128\/jb.178.1.306-308.1996","volume":"178","author":"H Okusu","year":"1996","unstructured":"Okusu, H., Ma, D. & Nikaido, H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol 178, 306\u2013308 (1996).","journal-title":"J Bacteriol"},{"key":"BFsrep22571_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/pr0504079","volume":"5","author":"CN Lok","year":"2006","unstructured":"Lok, C. N. et al. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. Journal of proteome research 5, 916\u2013924 (2006).","journal-title":"Journal of proteome research"},{"key":"BFsrep22571_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1128\/AAC.47.3.948-955.2003","volume":"47","author":"JE Bandow","year":"2003","unstructured":"Bandow, J. E., Brotz, H., Leichert, L. I., Labischinski, H. & Hecker, M. Proteomic approach to understanding antibiotic action. Antimicrobial agents and chemotherapy 47, 948\u2013955 (2003).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR22","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1128\/AAC.00078-11","volume":"55","author":"M Wenzel","year":"2011","unstructured":"Wenzel, M. et al. Proteomic signature of fatty acid biosynthesis inhibition available for in vivo mechanism-of-action studies. Antimicrobial agents and chemotherapy 55, 2590\u20132596 (2011).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1086\/510396","volume":"195","author":"DL Stevens","year":"2007","unstructured":"Stevens, D. L. et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195, 202\u2013211 (2007).","journal-title":"J Infect Dis"},{"key":"BFsrep22571_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/infdis\/jit129","volume":"208","author":"BA Diep","year":"2013","unstructured":"Diep, B. A. et al. Effects of Linezolid on Suppressing In Vivo Production of Staphylococcal Toxins and Improving Survival Outcomes in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia. J Infect Dis 208, 75\u201382 (2013).","journal-title":"J Infect Dis"},{"key":"BFsrep22571_CR25","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1093\/jac\/dkt073","volume":"68","author":"MP Otto","year":"2013","unstructured":"Otto, M. P. et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemoth 68, 1524\u20131532 (2013).","journal-title":"J Antimicrob Chemoth"},{"key":"BFsrep22571_CR26","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1128\/AAC.01080-12","volume":"56","author":"MJ Karau","year":"2012","unstructured":"Karau, M. J. et al. Linezolid Is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA Class II Transgenic Mice. Antimicrobial agents and chemotherapy 56, 5401\u20135405 (2012).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR27","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1128\/AAC.00123-08","volume":"52","author":"S Lemaire","year":"2008","unstructured":"Lemaire, S. et al. Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics. Antimicrobial agents and chemotherapy 52, 2797\u20132805 (2008).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jac\/dkp241","volume":"64","author":"FC Tenover","year":"2009","unstructured":"Tenover, F. C. & Goering, R. V. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. The Journal of antimicrobial chemotherapy 64, 441\u2013446 (2009).","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"BFsrep22571_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tim.2008.11.005","volume":"17","author":"C Garzoni","year":"2009","unstructured":"Garzoni, C. & Kelley, W. L. Staphylococcus aureus: new evidence for intracellular persistence. Trends in microbiology 17, 59\u201365 (2009).","journal-title":"Trends in microbiology"},{"key":"BFsrep22571_CR30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1302\/0301-620X.85B6.13509","volume":"85","author":"JK Ellington","year":"2003","unstructured":"Ellington, J. K. et al. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. The Journal of bone and joint surgery. British volume 85, 918\u2013921 (2003).","journal-title":"The Journal of bone and joint surgery. British volume"},{"key":"BFsrep22571_CR31","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","volume":"293","author":"VG Fowler Jr.","year":"2005","unstructured":"Fowler, V. G. Jr. et al. Staphylococcus aureus endocarditis: a consequence of medical progress. Jama 293, 3012\u20133021 (2005).","journal-title":"Jama"},{"key":"BFsrep22571_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jor.20003","volume":"24","author":"JK Ellington","year":"2006","unstructured":"Ellington, J. K. et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. Journal of orthopaedic research: official publication of the Orthopaedic Research Society 24, 87\u201393 (2006).","journal-title":"Journal of orthopaedic research: official publication of the Orthopaedic Research Society"},{"key":"BFsrep22571_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1574-6968.2009.01530.x","volume":"294","author":"MN Seleem","year":"2009","unstructured":"Seleem, M. N. et al. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline. FEMS microbiology letters 294, 24\u201331 (2009).","journal-title":"FEMS microbiology letters"},{"key":"BFsrep22571_CR34","doi-asserted-by":"publisher","first-page":"e0133877","DOI":"10.1371\/journal.pone.0133877","volume":"10","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Younis, W. & Seleem, M. N. Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens. PloS one 10, e0133877 (2015).","journal-title":"PloS one"},{"key":"BFsrep22571_CR35","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1086\/533594","volume":"46","author":"E Rubinstein","year":"2008","unstructured":"Rubinstein, E., Kollef, M. H. & Nathwani, D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 46 Suppl 5, S378\u2013385 (2008).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"BFsrep22571_CR36","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1086\/605572","volume":"49","author":"S Deresinski","year":"2009","unstructured":"Deresinski, S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 49, 1072\u20131079 (2009).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"BFsrep22571_CR37","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1086\/519474","volume":"45","author":"PC Appelbaum","year":"2007","unstructured":"Appelbaum, P. C. Microbiology of antibiotic resistance in Staphylococcus aureus. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 45 Suppl 3, S165\u2013170 (2007).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"BFsrep22571_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1128\/AAC.49.1.302-308.2005","volume":"49","author":"V Huang","year":"2005","unstructured":"Huang, V. & Rybak, M. J. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrobial agents and chemotherapy 49, 302\u2013308 (2005).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2334-7-111","volume":"7","author":"L Drago","year":"2007","unstructured":"Drago, L., De Vecchi, E., Nicola, L. & Gismondo, M. R. In vitro evaluation of antibiotics\u2019 combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC infectious diseases 7, 111 (2007).","journal-title":"BMC infectious diseases"},{"key":"BFsrep22571_CR40","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1128\/AEM.06923-11","volume":"78","author":"J Seras-Franzoso","year":"2012","unstructured":"Seras-Franzoso, J. et al. Disulfide bond formation and activation of Escherichia coli beta-galactosidase under oxidizing conditions. Applied and environmental microbiology 78, 2376\u20132385 (2012).","journal-title":"Applied and environmental microbiology"},{"key":"BFsrep22571_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00775-009-0466-z","volume":"14","author":"S Jackson-Rosario","year":"2009","unstructured":"Jackson-Rosario, S. et al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. Journal of biological inorganic chemistry: JBIC: a publication of the Society of Biological Inorganic Chemistry 14, 507\u2013519 (2009).","journal-title":"Journal of biological inorganic chemistry: JBIC: a publication of the Society of Biological Inorganic Chemistry"},{"key":"BFsrep22571_CR42","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1128\/JB.00164-09","volume":"191","author":"S Jackson-Rosario","year":"2009","unstructured":"Jackson-Rosario, S. & Self, W. T. Inhibition of selenium metabolism in the oral pathogen Treponema denticola. Journal of bacteriology 191, 4035\u20134040 (2009).","journal-title":"Journal of bacteriology"},{"key":"BFsrep22571_CR43","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.embor.7400126","volume":"5","author":"GV Kryukov","year":"2004","unstructured":"Kryukov, G. V. & Gladyshev, V. N. The prokaryotic selenoproteome. EMBO reports 5, 538\u2013543 (2004).","journal-title":"EMBO reports"},{"key":"BFsrep22571_CR44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/jac\/47.5.647","volume":"47","author":"AJ O\u2019Neill","year":"2001","unstructured":"O\u2019Neill, A. J., Cove, J. H. & Chopra, I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. The Journal of antimicrobial chemotherapy 47, 647\u2013650 (2001).","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"BFsrep22571_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"LL Ling","year":"2015","unstructured":"Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455\u2013459 (2015).","journal-title":"Nature"},{"key":"BFsrep22571_CR46","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/cmi.12130","volume":"15","author":"BG Surewaard","year":"2013","unstructured":"Surewaard, B. G. et al. Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis. Cellular microbiology 15, 1427\u20131437 (2013).","journal-title":"Cellular microbiology"},{"key":"BFsrep22571_CR47","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1128\/AAC.02578-14","volume":"58","author":"MF Mohamed","year":"2014","unstructured":"Mohamed, M. F., Hamed, M. I., Panitch, A. & Seleem, M. N. Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides. Antimicrobial agents and chemotherapy 58, 4113\u20134122 (2014).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR48","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fmicb.2015.00750","volume":"6","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Younis, W. & Seleem, M. N. Repurposing celecoxib as a topical antimicrobial agent. Frontiers in microbiology 6, 750 (2015).","journal-title":"Frontiers in microbiology"},{"key":"BFsrep22571_CR49","doi-asserted-by":"publisher","first-page":"16407","DOI":"10.1038\/srep16407","volume":"5","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S. et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Scientific reports 5, 16407 (2015).","journal-title":"Scientific reports"},{"key":"BFsrep22571_CR50","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1021\/ac200812d","volume":"83","author":"GL Andrews","year":"2011","unstructured":"Andrews, G. L., Simons, B. L., Young, J. B., Hawkridge, A. M. & Muddiman, D. C. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Analytical chemistry 83, 5442\u20135446 (2011).","journal-title":"Analytical chemistry"},{"key":"BFsrep22571_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature biotechnology 26, 1367\u20131372 (2008).","journal-title":"Nature biotechnology"},{"key":"BFsrep22571_CR52","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1128\/AAC.47.7.2283-2292.2003","volume":"47","author":"C Seral","year":"2003","unstructured":"Seral, C., Van Bambeke, F. & Tulkens, P. M. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 47, 2283\u20132292 (2003).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep22571_CR53","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.2174\/1381612821666150506154434","volume":"21","author":"W Younis","year":"2015","unstructured":"Younis, W. & Thangamani, S. & Seleem, M.N. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. Current pharmaceutical design 21, 4106\u20134111 (2015).","journal-title":"Current pharmaceutical design"},{"key":"BFsrep22571_CR54","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"J Meletiadis","year":"2010","unstructured":"Meletiadis, J., Pournaras, S., Roilides, E. & Walsh, T. J. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrobial agents and chemotherapy 54, 602\u2013609 (2010).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep22571_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nature13445","volume":"510","author":"AM King","year":"2014","unstructured":"King, A. M. et al. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510, 503\u2013506 (2014).","journal-title":"Nature"},{"key":"BFsrep22571_CR56","first-page":"5749","volume":"9","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Nepal, M., Chmielewski, J. & Seleem, M. N. Antibacterial activity and therapeutic efficacy of Fl-P(R)P(R)P(L)-5, a cationic amphiphilic polyproline helix, in a mouse model of staphylococcal skin infection. Drug design, development and therapy 9, 5749\u20135754 (2015).","journal-title":"Drug design, development and therapy"},{"key":"BFsrep22571_CR57","doi-asserted-by":"publisher","first-page":"e0130385","DOI":"10.1371\/journal.pone.0130385","volume":"10","author":"H Mohammad","year":"2015","unstructured":"Mohammad, H. et al. Antibacterial Characterization of Novel Synthetic Thiazole Compounds against Methicillin-Resistant Staphylococcus pseudintermedius. PloS one 10, e0130385 (2015).","journal-title":"PloS one"},{"key":"BFsrep22571_CR58","doi-asserted-by":"publisher","first-page":"e116259","DOI":"10.1371\/journal.pone.0116259","volume":"9","author":"MF Mohamed","year":"2014","unstructured":"Mohamed, M. F., Hammac, G. K., Guptill, L. & Seleem, M. N. Antibacterial activity of novel cationic peptides against clinical isolates of multi-drug resistant Staphylococcus pseudintermedius from infected dogs. PloS one 9, e116259 (2014).","journal-title":"PloS one"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep22571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22571","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T22:49:31Z","timestamp":1672872571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep22571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3,21]]}},"alternative-id":["BFsrep22571"],"URL":"https:\/\/doi.org\/10.1038\/srep22571","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]},"assertion":[{"value":"21 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22571"}}